van Velsen, Jort S.
van der Vegt, Bert
Plaat, Boudewijn E. C.
Langendijk, Johannes A.
Epskamp-Kuijpers, Chantal C. H. J.
van Dijk, Boukje A. C.
Oosting, Sjoukje F.
Article History
Received: 21 September 2023
Accepted: 2 December 2023
First Online: 29 January 2024
Declarations
:
: S.F.O. reports a research contract with Merck KGaA, consultancy fees from Bristoll Myers Squibb, Genmab and Merck KGaA (paid to the institution) and unpaid consultancy for ALX Oncology. B.v.d.V. reports honoraria received by the University Medical Center Groningen for expertise or scientific advisory board/consultancy from Visiopharm, Philips, MSD/Merck, Daiichi-Sankyo/AstraZenica; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. B.E.C.P. reports research grants, consultancy fees and honoraria from Olympus EU. J.A.L. reports consultancy fees from IBA and RaySearch laboratories, and collaborative research contracts with IBA, RaySearch laboratories, Elekta, Mirada and Siemens. All other authors have no potential conflicts of interest.
: Since the data were anonymized, ethics approval was not required.
: Not applicable.
: Not applicable.